{"address1": "1-1, Nihonbashi-Honcho 2-chome", "address2": "Chuo-ku", "city": "Tokyo", "zip": "103-8668", "country": "Japan", "phone": "81 3 3278 2111", "fax": "81 3 3278 2000", "website": "https://www.takeda.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.", "fullTimeEmployees": 49095, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christophe  Weber", "age": 57, "title": "President, CEO & Representative Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 572000000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Constantine  Saroukos", "age": 52, "title": "CFO & Representative Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 356000000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew S.  Plump", "age": 58, "title": "President of Research & Development and Representative Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 408000000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Seigo  Izumo", "title": "Chair of Management Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Haruhiko  Hirate", "age": 66, "title": "Member of Management Board", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Salvatore  Alesci M.D., Ph.D.", "age": 48, "title": "Member of Management Board and Head of R&D Global Science & Biomedical Policy", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Norimasa  Takeda", "title": "Chief Accounting Officer & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iwaaki  Taniguchi", "title": "Senior Vice President of Corporate Finance & Controlling Department", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gabriele  Ricci", "age": 45, "title": "Chief Data & Technology Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher David  O'Reilly", "title": "Global Head of Investor Relations & Global Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 1, "compensationRisk": 1, "shareHolderRightsRisk": 5, "overallRisk": 1, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 4381.0, "open": 4378.0, "dayLow": 4371.0, "dayHigh": 4383.0, "regularMarketPreviousClose": 4381.0, "regularMarketOpen": 4378.0, "regularMarketDayLow": 4371.0, "regularMarketDayHigh": 4383.0, "dividendRate": 188.0, "dividendYield": 0.0429, "exDividendDate": 1711584000, "payoutRatio": 1.6361, "fiveYearAvgDividendYield": 4.67, "beta": 0.539, "trailingPE": 38.87557, "forwardPE": 27.711302, "volume": 544300, "regularMarketVolume": 544300, "averageVolume": 4461447, "averageVolume10days": 4806230, "averageDailyVolume10Day": 4806230, "bid": 4379.0, "ask": 4377.0, "marketCap": 6867118981120, "fiftyTwoWeekLow": 3900.0, "fiftyTwoWeekHigh": 4873.0, "priceToSalesTrailing12Months": 1.6471667, "fiftyDayAverage": 4346.42, "twoHundredDayAverage": 4360.4, "trailingAnnualDividendRate": 184.0, "trailingAnnualDividendYield": 0.041999545, "currency": "JPY", "enterpriseValue": 11792020406272, "profitMargins": 0.04275, "floatShares": 1549899702, "sharesOutstanding": 1568909952, "heldPercentInsiders": 0.00032000002, "heldPercentInstitutions": 0.43007, "impliedSharesOutstanding": 1582729984, "bookValue": 4297.215, "priceToBook": 1.0185667, "lastFiscalYearEnd": 1680220800, "nextFiscalYearEnd": 1711843200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.113, "netIncomeToCommon": 178219008000, "trailingEps": 112.59, "forwardEps": 157.95, "pegRatio": 4.22, "enterpriseToRevenue": 2.828, "enterpriseToEbitda": 9.758, "52WeekChange": 0.029875278, "SandP52WeekChange": 0.32311738, "lastDividendValue": 94.0, "lastDividendDate": 1711584000, "exchange": "JPX", "quoteType": "EQUITY", "symbol": "4502.T", "underlyingSymbol": "4502.T", "shortName": "TAKEDA PHARMACEUTICAL CO LTD", "longName": "Takeda Pharmaceutical Company Limited", "firstTradeDateEpochUtc": 946944000, "timeZoneFullName": "Asia/Tokyo", "timeZoneShortName": "JST", "uuid": "fb2ad09e-f947-34fe-9b90-a37a3155bad5", "messageBoardId": "finmb_874540", "gmtOffSetMilliseconds": 32400000, "currentPrice": 4377.0, "targetHighPrice": 5800.0, "targetLowPrice": 4200.0, "targetMeanPrice": 4820.0, "targetMedianPrice": 4800.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 16, "totalCash": 288358989824, "totalCashPerShare": 183.795, "ebitda": 1208410046464, "totalDebt": 5206289940480, "quickRatio": 0.452, "currentRatio": 1.064, "totalRevenue": 4169049047040, "debtToEquity": 77.215, "revenuePerShare": 2670.942, "returnOnAssets": 0.02611, "returnOnEquity": 0.027609998, "freeCashflow": -9876374528, "operatingCashflow": 731448999936, "earningsGrowth": -0.121, "revenueGrowth": 0.013, "grossMargins": 0.67761004, "ebitdaMargins": 0.28985, "operatingMargins": 0.09442, "financialCurrency": "JPY", "trailingPegRatio": 3.4628}